Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

SPDR® S&P Biotech ETF (XBI)

Delayed Data
As of May 26
 -1.04 / -1.49%
Today’s Change
Today|||52-Week Range

Investment Objective

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.


1 month-2.70% 3 years+17.68%
3 months+2.08% 5 years+20.76%
1 year+22.55% Since inception+13.83%
Data through 05/27/2017

Quote Details

Previous close$69.76
Open day’s range68.55 – 69.83
Net asset value (NAV)68.69 (05/26/2017)
Daily volume3,614,442
Average volume (3 months)4,219,276
Data as of 7:59pm ET, 05/26/2017

Peer Comparisonvs. Health ETFs

Performance 5-yr return+20.76%+16.30%
Expense Gross exp ratio0.35%1.32%
Risk 5 year sharpe ratio0.801.08
Net assets$3.3B$3.0B
Average market cap$5.1B$28.8B
Average P/E--23.8
Dividend / Share--0.30%


XLV Health Care Select Sector SPDR® Fund
FHLC Fidelity® MSCI Health Care Index ETF
VHT Vanguard Health Care Index Fund ETF Shar...


Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
VRTX Vertex Pharmaceuticals Inc3.00%
IONS Ionis Pharmaceuticals Inc2.74%
SRPT Sarepta Therapeutics Inc2.65%
BIVV Bioverativ Inc2.64%
EXAS Exact Sciences Corp2.62%
NBIX Neurocrine Biosciences Inc2.50%
BMRN Biomarin Pharmaceutical Inc2.47%
EXEL Exelixis Inc2.47%
GILD Gilead Sciences2.40%
SGEN Seattle Genetics Inc2.40%